Search the Newsreel

EDIT Q2 Earnings Beat Estimates, Revenues Rise, Pipeline in Focus

Editas Medicine (EDIT) reported a narrower-than-expected loss of 15 cents per share in Q2 2026, with revenues significantly surpassing estimates at $11.9 million due to deferred revenues. The company's lead gene-editing candidate, EDIT-401, for heterozygous familial hypercholesterolemia, showed encouraging preclinical data with rapid and …

Editas Medicine, Inc. 2026: Revenue $11.89M, EPS ($0.15) — 10-Q Summary

Editas Medicine, Inc. reported an increase in collaboration and research revenue to $11.89M for the quarter ended 2026, with a reduced net loss of ($18.23M) and improved diluted EPS of ($0.15). Key highlights include the nomination of EDIT-401 as the lead in vivo candidate …

Praxis Precision Medicines (NASDAQ:PRAX) Sets New 12-Month High Following Better-Than-Expected Earnings

Disc Medicine (IRON): FMR LLC, Abigail Johnson report 12.8% ownership of common stock

FMR LLC and Abigail P. Johnson have reported an updated beneficial ownership of 12.8% of Disc Medicine Inc. (IRON) common stock, totaling 4,875,472.97 shares, through an Amendment No. 4 to a Schedule 13G filing. FMR LLC holds sole voting power over 4,875,263 shares and …

Prime Medicine, Inc. (PRME) Reports Q2 Loss, Misses Revenue Estimates

Prime Medicine, Inc. (PRME) reported a Q2 loss of $0.24 per share, aligning with Zacks Consensus Estimate but missing revenue estimates significantly at $1.15 million. The company has consistently missed revenue expectations over the last four quarters, and its shares have underperformed the S&P …

Praxis Precision Medicines stock hits 52-week high at 366.7 USD

Praxis Precision Medicines Inc. (PRAX) has reached a new 52-week high of $366.70, reflecting a 557% one-year return and a market cap of $9.92 billion, despite an InvestingPro analysis suggesting it may be overvalued. The company recently reported a Q2 2026 loss of $2.87 …

Earnings Flash (PRAX) Praxis Precision Medicines Posts Q2 Loss $2.87 a Share, vs. FactSet Est of $3.64 Loss

HC Wainwright Forecasts Strong Price Appreciation for Disc Medicine (NASDAQ:IRON) Stock

HC Wainwright has increased its price target for Disc Medicine (NASDAQ:IRON) to $120 from $118, maintaining a "Buy" rating and suggesting a 52% upside. Analyst sentiment is generally positive, with a consensus "Moderate Buy" rating and an average target of $106. Despite beating quarterly …

Generate Biomedicines Shares Fall Following Q2 Financial Results

Generate Biomedicines (GENB) shares dropped by 4.6% after the company announced its Q2 financial results, indicating a wider loss than expected. The full details of the financial performance are behind a premium paywall.

Praxis Precision Medicines beats Q2 loss estimates; shares rise

Praxis Precision Medicines Inc. (NASDAQ:PRAX) reported a Q2 loss of $2.87 per share, outperforming analyst estimates. The company's shares rose 6.5% in premarket trading following the news, which also highlighted progress with FDA interactions for its drug candidates ulixacaltamide HCl and relutrigine, and a …

Sei Investments Co. Buys 86,585 Shares of Cinemark Holdings Inc $CNK

Sei Investments Co. significantly increased its stake in Cinemark Holdings Inc (CNK) by 113.9% in the first quarter, now owning 162,635 shares valued at approximately $4.64 million. Several other institutional investors also increased their positions. Analysts maintain a "Moderate Buy" rating for Cinemark, with …

Here's How Much a $1000 Investment in Cintas Made 10 Years Ago Would Be Worth Today

For most investors, how much a stock's price changes over time is important. This factor can impact your investment portfolio as well as help you compare investment results across sectors and industries. The fear of missing out, or FOMO, also plays a factor in …

FDA milestones and Beam ruling frame outlook for Prime Medicine (NASDAQ: PRME)

Earnings Flash (GENB) Generate Biomedicines Inc. Reports Q2 Revenue $6.3M

Generate Biomedicines (GENB) posts Q2 loss but holds $457.4M cash after IPO

Janus Henderson Group PLC Purchases 8,623 Shares of Cintas Corporation $CTAS

Janus Henderson Group PLC increased its stake in Cintas Corporation (NASDAQ:CTAS) by 20% in the first quarter, acquiring an additional 8,623 shares, bringing their total holdings to 51,716 shares valued at $8.75 million. Cintas has consistently exceeded quarterly expectations, reporting strong revenue growth and …

Pacer Advisors Inc. Lowers Stake in Cintas Corporation $CTAS

Pacer Advisors Inc. significantly reduced its stake in Cintas Corporation (NASDAQ:CTAS) by 34.8% in the first quarter, selling over 21,000 shares. Despite this, Cintas continues to exceed earnings expectations, reporting $1.29 EPS and $2.91 billion in revenue, and has increased its quarterly dividend. The …

Q2 2026 Praxis Precision Medicines Inc Earnings Call Transcript

Praxis Precision Medicines Inc. held its Q2 2026 earnings call, discussing positive FDA feedback for ulixacaltamide and relutrigine, and strong financial positioning with $1.4 billion in cash. The company also addressed the setback in its vormatrigine program and reported increased operating expenses and cash …

Generate Biomedicines (Nasdaq:GENB) - Stock Analysis

Generate Biomedicines (GENB) is utilizing machine learning for drug discovery and development, holding a market cap of US$1.8 billion. While revenue is projected to grow significantly, the company is currently unprofitable and faces risks such as declining earnings forecasts and a cash runway of …

Quantinno Capital Management LP Boosts Stake in Revolution Medicines, Inc. $RVMD

Quantinno Capital Management LP significantly increased its stake in Revolution Medicines (RVMD) by 97.6% in the first quarter, now owning 63,360 shares valued at $6.16 million. Despite the company reporting a wider-than-expected quarterly loss of $3.06 per share, institutional investors hold 94.34% of the …

Dimensional Fund Advisors LP Raises Holdings in Disc Medicine, Inc. $IRON

Dimensional Fund Advisors LP significantly increased its stake in Disc Medicine, Inc. (NASDAQ:IRON) by 76.4% in the first quarter, now holding 394,447 shares valued at $25.2 million. Despite insider selling totaling $7.6 million, institutional investors collectively own 83.7% of the company. Analysts maintain a …

Disc Medicine (IRON) Slips 1.86% as Biotech Stock Tests Key Support Zone - Analyst Upgrade Stocks

Cineverse (CNVS) Expected to Announce Earnings on Thursday

Curious about National CineMedia (NCMI) Q2 Performance? Explore Wall Street Estimates for Key Metrics

Prime Medicine (PRME) Earnings Date and Reports 2026

Praxis Precision Medicines (PRAX) Earnings Date and Reports 2026

Cineverse sets Aug. 13 call to discuss quarterly results

A Closer Look at Vicinity Centres’ (ASX:VCX) Latest Market Move and Property Position

Revolution Medicines (NASDAQ:RVMD) Announces Earnings Results

Cinemark Holdings (CNK) Is Up 8.6% After Record Spider-Man Weekend And Q2 Results - Has The Bull Case Changed?

Cinemark Holdings (CNK) saw an 8.6% increase after a record-breaking "Spider-Man: Brand New Day" weekend and strong Q2 2026 results, with revenue reaching US$1,086.4 million and net income US$139.4 million. While these results bolster the short-term bull case, they also highlight the company's reliance …

Press Release: Editas Medicine Announces Second Quarter 2026 Results and Business Updates

Editas Medicine (NASDAQ: EDIT) announced its second quarter 2026 financial results and provided business updates. The company highlighted recent progress in its CRISPR-based therapeutic programs and discussed its financial position, offering insights into its strategic direction and upcoming milestones for the remainder of the …

CX Institutional Acquires 31,548 Shares of Cincinnati Financial Corporation $CINF

CX Institutional significantly increased its stake in Cincinnati Financial Corporation (NASDAQ:CINF) by 1,405.9% in the second quarter, purchasing an additional 31,548 shares. This brings their total holdings to 33,792 shares, valued at approximately $6.26 million. Despite missing the consensus earnings estimate for the quarter, …

Earnings call transcript: Revolution Medicines lifts spending outlook in Q2 2026

Revolution Medicines ended Q2 2026 with $3.9 billion in cash and investments and increased its 2026 spending forecast to $2.1 billion to $2.2 billion to advance late-stage oncology programs and prepare for a potential first product launch. The company's lead drug, daraxonrasib, cleared a …

Editas Medicine (NASDAQ:EDIT) Issues Earnings Results

Editas Medicine (NASDAQ:EDIT) announced its quarterly earnings, reporting an adjusted loss of $0.15 per share, surpassing the consensus estimate of a $0.27 loss, with revenue of $11.89 million, significantly exceeding analyst expectations of $2.85 million. Despite beating revenue and EPS estimates, the company remains …

Revolution Medicines Q2 Net Loss Widens

Revolution Medicines reported a significant widening of its net loss in Q2, increasing to $111.4 million from $70.8 million year-over-year, largely due to increased research and development expenses. Despite the loss, the company exceeded revenue expectations with $9.3 million, up from $2.1 million in …

Editas Medicine (EDIT) Reports Q2 Loss, Beats Revenue Estimates

Editas Medicine (EDIT) reported a Q2 loss of $0.15 per share, surpassing the Zacks Consensus Estimate of a $0.3 loss and representing a 50% surprise. The company also beat revenue estimates with $11.89 million, significantly higher than the $3.58 million from the previous year. …